🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our review on DDIs in prostate Ca is now published ESMO Open! Coskun YAZGAN Thanks to Yüksel Ürün silke gillessen Rana McKay, MD, FASCO Emre Yekedüz and Marina Kaymakcalan for their support. authors.elsevier.com/sd/article/S20…

Dear Colleagues at #ASCO25 As we gear up for an Exciting day of GU oncology here in Chicago, A warm invite from our partners at Advanced Prostate Cancer Consensus Conference to Join us in Lugano🇨🇭Switzerland for the Advanced #ProstateCancer Consensus Conference. Here are silke gillessen & aurelius omlin to tell us

Dear Colleagues at #ASCO25 As ALWAYS, it is a pleasure for OncoAlert 🚨 to be around to capture yet another GREAT Uromigos discussion by Tom Powles 🇬🇧& Brian Rini, MD 🇺🇸 Here they are lakeside discussing Final Results of IO-Based Combination in mRCC Ping OncoAlert GU Faculty

🗣️Prostate Oral Abstract #ASCO25 👉Abst5000: Dr #TedDeWeese presenting #CAN2409+prodrug +EBRT +/-ADT in Int/High Risk PCa #CAN2409 is a replication-defective adenovirus 🦠HSV-tk gene 🧬 w/ prodrug promoting immunogenic cell death ☠️ and immunize 💉against tumor antigens for

Phase 3 of novel viral vector in #prostatecancer pts getting XRT. Intermediate to high-risk. Despite slide title - only helps w/o ADT but not w/ADT. Curves separate at 24 mos when biopsies done. Unlikely to help high risk w/ADT but may replace ADT for intermediate risk? #ASCO25

Primary results from phase 3 #AMPLITUDE trial showing significant benefits to adding #niraparib, a #PARPi, to mHSPC patients with HRR mutations. Great to have new options to treat #prostatecancer pts who have HRR mutations which portends a poor prognosis. #ASCO25

🗣️Prostate Oral Abstract #ASCO25 👉LBA5006: Dr #GerhardtAttard presenting ABI +/- #Niraparib in #HRRdeficient mCSPC on #AMPLITUDE n = 696 pts 🧬germline / somatic HRR gene alterations - BRCA1/BRCA2 (55.6%) - BRIP1, CDK12, CHEK2, FANCA, PALB2, RAD51B, RAD54L (44.4%) high-vol

📢 #ASCO25 | Major advance in mCRPC with bone mets by the one and only Rana McKay, MD, FASCO | Olaparib + Ra-223 vs Ra-223 Alone Ph. II | In a randomized study n=120, this combo doubled rPFS (8.6 vs 4.0 mo; HR 0.51) in both HRR-mut and HRR-wt patients — with manageable safety. A

#ASCO25 | CabCarb + Cetrelimab Induction → Niraparib +/- Cetrelimab Ph. II | Aggressive Variant Prostate Cancer: In AVPC n=120, CabCarb + Cet induction followed by Nira + Cet vs Nira alone yields PFS 5.6 mo vs 3.4 mo and OS 24.3 mo vs 10.2 mo; scRNA-seq shows increased

Impressive data, especially for pts with BRCAm, but in mHSPC, for once not in RCC. Sorry, Tom! Compliments to AttardLab and team!

Great presentation by Rana McKay, MD, FASCO on COMRADE trial! Interesting results supporting hypothesis of potential additive effect with Ra223 + olaparib! Subset analysis suggested benefit might be regardless of HRR+ (caveat small N) UroToday.com OncoAlert #ASCO25 Neeraj Agarwal, MD, FASCO Toni Choueiri, MD

Great presentation! Just to mention that we are also launching De-Escalate (EORTC 2238-GUCG) a pragmatic trial testing intermittent therapy in the good responders. We just opened the first centers. Anyone who is interested to participate please contact me or tombal

Just announced at #ASCO25: The ArteraAI Prostate Test is now enhanced for high-risk localized prostate cancer—helping identify which patients benefit from abiraterone and who may safely avoid added toxicity, cost, and complexity: itnonline.com/content/prosta…

In 2023, the FDA approved belzutifan for certain kidney cancers –– thanks to years of work led by Nobel Prize recipient William G. Kaelin Jr., MD, KaelinLab. Now, Toni Choueiri, MD, director of Dana-Farber Lank Center for Genitourinary Oncology, and team are working to expand its clinical use. bit.ly/3GNeb9D

Compliments to Mark and all the team for this interesting paper!

Wonderful initiative! Kudos to Vedang Murthy exactly spirit of Advanced Prostate Cancer Consensus Conference to spread knowledge and initiate discussions. Recommendations have to be adapted to regional specifities. Hope to see many South Asians Advanced Prostate Cancer Consensus Conference in Lugano 30th April, registration anar rahimov.org

Compliments Toni Choueiri, MD!

ESMO Living Guidelines on Renal Cell Carcinoma Are Out ESMO - Eur. Oncology Yüksel Ürün Tom Powles silke gillessen oncodaily.com/blog/esmo-livi… #Cancer #CancerResearch #KidneyCancer #RCC #MedX #MedNews #MedEd #RenalCellCarcinoma #CancerTreatment #Guidelines #Medicine #Health #Oncology

Compliments, dear Samra and all the best!